Hengrui Pharmaceuticals Makes Successful IPO Debut on Hong Kong Stock Exchange

Jiangsu Hengrui Pharmaceuticals, China’s leading pharmaceutical company, successfully launched its IPO in Hong Kong on May 23rd, 2025, raising HK$9.9 billion. This marks a significant development for Hong Kong’s IPO market, demonstrating strong investor confidence in the region’s financial landscape. The company priced its shares at HK$44.05 per share, and they surged significantly in early trading, signaling a robust reception from investors. 455 times oversubscription was reported, indicating substantial demand. Hengrui Pharmaceuticals plans to utilize the funds for expanding drug development, potential acquisitions, and production capacity increases.